Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ulmus crassifolia pollen is an allergenic extract derived from the pollen of the Cedar Elm tree (Ulmus crassifolia). It is a biologic product used for diagnostic purposes, specifically for percutaneous (prick/scratch) or intradermal skin testing. [4, 6] The extract helps to diagnose Type I hypersensitivity (allergy) to cedar elm pollen in individuals showing allergic symptoms. [7, 13] The mechanism involves the allergen in the extract binding to and cross-linking IgE antibodies on the surface of mast cells in the skin of a sensitized person. This action triggers the degranulation of mast cells and the release of histamine and other chemical mediators, which produces a characteristic wheal and erythema (flare) reaction, confirming sensitivity to the allergen. [1, 14] This product is categorized as a non-standardized allergenic extract and is developed and distributed by companies such as ALK-Abello, Inc. [5, 6, 9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ulmus crassifolia pollen.